Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Schizophrenia, Cobenfy
Cobenfy: The First New Schizophrenia Drug in Decades
The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other antipsychotics.
Cobenfy Approved for Adult Patients with Schizophrenia
The Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride) for the treatment of adults with schizophrenia.
FDA Approves Cobenfy, Pioneering New Approach to Schizophrenia Treatment
The U.S. Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride) for the treatment of schizophrenia in adults. This innovative medication marks a significant
BMS achieves FDA approval for schizophrenia drug Cobenfy
Bristol Myers Squibb (BMS) acquired Karuna Therapeutics, the developer of KarXT, in a deal worth US $14.0 billion in equity value that completed ​ earlier this year. The deal has paid off as Karuna’s lead asset was approved ​ last week by the US FDA.
FDA Approves the First New Schizophrenia Drug in Decades
Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely different way from existing medications for schizophrenia, which is building excitement and enthusiasm among doctors and patients alike.
Experts hail new schizophrenia drug Cobenfy as a game-changer, the ‘first of its kind’
Cobenfy is the first schizophrenia drug in decades to treat the mental health condition in a new way, with potentially fewer side effects British scientists have hailed the US approval of a new drug for schizophrenia,
FDA approves Cobenfy, a first-in-class schizophrenia drug
The US Food and Drug Administration has approved Cobenfy, also known as KarXT, a new schizophrenia treatment. The drug was developed by Karuna Therapeutics, which was bought by Bristol Myers Squibb (BMS) last year for $14 billion.
FDA Approves groundbreaking drug for schizophrenia treatment
On Thursday, the U.S. Food and Drug Administration (FDA) approved the drug Cobenfy which targets schizophrenia in a new way. Cobenfy (xanomeline and trospium chloride) capsules are the first antipsychotic drug approved to target cholinergic receptors. All other treatments available for schizophrenia target the dopamine receptors.
First New Schizophrenia Treatment in Decades a Much-Needed Alternative
"This drug takes the first new approach to schizophrenia treatment in decades," Tiffany Farchione, a top official in the US Food and Drug Administration (FDA), said in a statement Thursday. "This approval offers a new alternative to the antipsychotic medications people with schizophrenia have previously been prescribed,
clinicaltrialsarena
1d
A schizophrenia win for BMS’ Cobenfy, but challenges lie ahead
On 26 September 2024, Bristol Myers Squibb (BMS) announced that the US Foof and Drug Administration approved Cobenfy ...
BioSpace
2d
The Making of BMS’ Cobenfy: From Alzheimer’s to Schizophrenia
From Eli Lilly to Karuna Therapeutics to current owner Bristol Myers Squibb, the newly approved schizophrenia drug had quite ...
6d
Cobenfy Approval Brings 20% Upside To Bristol Myers Squibb Stock
This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Trending now
Court filing made public
Helene's wake
WW2-era bomb explodes
Strike leads to panic-buying
Kirk now Category 3
5 Chinese nationals charged
Ex-detective denied parole
California gang busted
OH gov. declares emergency
Golf Hall of Famer dies
'Rust' gets premiere date
Expands online recruitment
US bans 2 Chinese firms
US diagnostic errors study
‘Ryan's Hope' actor dies
Fifth recall within a year
Record heat bakes millions
Student loan plan ruling
Fruit fly brain mapped
FDA: No longer in shortage
Dream fire coach Wright
To hire 250,000 workers
Weekly jobless claims rise
CA deepfakes law blocked
Israel strikes central Beirut
Mortgage rate ticks up
Related topics
Coventry
Food and Drug Administration
Blackburn
Bristol-Myers Squibb
Feedback